Congenital Hepatic Fibrosis Workup
- Author: Hisham Nazer, MB, BCh, FRCP, , DTM&H; Chief Editor: Carmen Cuffari, MD more...
The following studies are indicated in congenital hepatic fibrosis:
- Liver function tests
- Liver enzyme levels are usually within the reference range when uncomplicated by portal hypertension or cholangitis.
- Serum alkaline phosphatase and gamma-glutamyl transpeptidase (GGT) levels may be elevated.
- In the presence of cholangitis, serum bilirubin levels, alanine aminotransferase (ALT) levels, aspartate aminotransferase (AST) levels, WBCs, and the erythrocyte sedimentation rate (ESR) may be elevated.
- The presence of leukopenia and thrombocytopenia provides evidence of hypersplenism. Furthermore, thrombocytopenia and splenomegaly may be the only manifestations of the disease.
- Splenic pressure is elevated.
- Renal function
- Renal dysfunction is present in approximately 20% of patients.
- In the presence of renal involvement, serum urea and serum creatinine levels are elevated, whereas creatinine clearance is decreased.
Characteristic imaging features are generally present and increased recognition of these findings may obviate the need for routine liver biopsy while preserving diagnostic accuracy. Imaging is used in both initial diagnosis and follow-up of patients. However, the hepatobiliary imaging findings of congenital hepatic fibrosis may not be detected until later. The combination of conventional and high-resolution ultrasonography with magnetic resonance cholangiography allows the definition of the extent of liver and renal disease without requiring ionizing radiation and contrast agents.
- This study helps to further support the diagnosis by revealing evidence of a patchy pattern of intense hepatic echogenicity, portal hypertension, splenomegaly, and intrahepatic and extrahepatic biliary cysts and dilatations. It is the first-line modality used in the diagnostic process because of its lack of radiation and its capability of detecting renal and liver abnormalities.
- Ultrasonographic evaluation should include Doppler flow studies to assess the patency of the portal vasculature.
- Evidence of nephromegaly and increased echogenicity with polycystic changes add further support to the diagnosis of congenital hepatic fibrosis (CHF)-ARPKD.
- Ultrasonography of liver and kidneys are also indicated as part of preparation for liver and renal biopsies.
- Color Doppler ultrasonography assists in evaluating the portal venous system. It shows the direction of portal blood flow and varicose venous collaterals.
- CT scanning: CT scanning of the abdomen is occasionally indicated as part of the imaging studies for further evaluation of hepatic and renal involvement in congenital hepatic fibrosis. CT scanning can demonstrate the abnormal shape and size of the liver. It can also show the periportal thickening, varices, and splenomegaly. In patients with renal insufficiency, contrast medium is not administered, limiting the study.
- Intravenous pyelography
- Intravenous pyelography (IVP) findings may be abnormal, revealing nephromegaly and alternation of radiodense and radiolucent streaks radiating from the medulla to the cortex.
- This study is not mandatory for the diagnosis of congenital hepatic fibrosis with potential renal involvement.
- This study may reveal an abnormality of the intrahepatic portal venous system characterized by duplication of the venous channels.
- Naturally occurring splenorenal or gastrorenal shunts with increasing collateral formation may also be observed.
- This test further reveals the details of the vascular anatomy and its patency, as well as the extent of the variceal formation.
- Transhepatic cholangiography is a safe and direct means of identifying cholangitis.
- MRI and magnetic resonance cholangiopancreatography: Magnetic resonance cholangiopancreatography (MRCP) is described as a sensitive method for detecting biliary abnormalities, even when ultrasonographic findings are normal. It may reveal the unusual distribution of the biliary tree with mild dilatation peripherally and poor visibility centrally. MRI can reveal portal hypertension and periportal fibrosis and may help in the preoperative planning of the affected children with the cholangitic form of congenital hepatic fibrosis, obviating the need for invasive cholangiography.
See the list below:
- Endoscopic examination
- Upper GI endoscopy is often required in the overall evaluation of patients with congenital hepatic fibrosis, especially in the presence of anemia and/or a history of hematemesis or melena.
- Endoscopy is helpful to confirm or rule out the presence of varices, erosions, or ulceration.
- In bleeding varices, the procedure is followed by sclerotherapy or band ligation.
- Liver biopsy
- The diagnosis of congenital hepatic fibrosis depends on histological liver biopsy findings, preferably obtained through minilaparotomy (wedge liver biopsy) to ensure examination of a sufficient number of portal tracts to support the diagnosis.
- A percutaneous liver biopsy may produce sufficient tissue to confirm the diagnosis; findings may reveal the histological changes in the portal tracts. Remember that the pathological lesions may not be uniform throughout the liver; therefore, the percutaneous liver biopsy may prove inadequate to support the diagnosis. Furthermore, cases with one-lobe involvement have been reported.
- Congenital hepatic fibrosis is characterized by fibrous enlargement of the portal tracts, which contain variable numbers of abnormally shaped bile ducts.
See the list below:
- Liver histology, as revealed through the biopsy, reveals extensive hepatic fibrosis. The widened fibrous bands in the portal tract contain an increased number of ectatic and dysplastic branches of the interlobular bile ducts. The irregularly shaped proliferating bile ducts are lined by normal cuboidal epithelium.
- The hepatic lobules are usually normal. See the image below.
- Cholestasis is observed in association with cholangitis. Other findings include portal vein branch hypoplasia and degeneration of the bile duct epithelium. Hypoplasia of the portal vein branches in association with supernumerous hepatic artery branches is also observed.
Lipschitz B, Berdon WE, Defelice AR, Levy J. Association of congenital hepatic fibrosis with autosomal dominant polycystic kidney disease. Report of a family with review of literature. Pediatr Radiol. 1993. 23(2):131-3. [Medline].
Hoyer PF. Clinical manifestations of autosomal recessive polycystic kidney disease. Curr Opin Pediatr. 2015 Apr. 27 (2):186-92. [Medline].
Bristowe F. Cystic disease of the liver associated with similar disease of the kidney. Trans Pathol Soc Lond. 1856. 5:229.
Kerr DN, Harrison CV, Sherlock S, Walker RM. Congenital hepatic fibrosis. Q J Med. 1961 Jan. 30:91-117. [Medline].
O'Brien K, Font-Montgomery E, Lukose L, Bryant J, Piwnica-Worms K, Edwards H, et al. Congenital hepatic fibrosis and portal hypertension in autosomal dominant polycystic kidney disease. J Pediatr Gastroenterol Nutr. 2012 Jan. 54 (1):83-9. [Medline].
Akhan O, Karaosmanoglu AD, Ergen B. Imaging findings in congenital hepatic fibrosis. Eur J Radiol. 2007 Jan. 61(1):18-24. [Medline].
Desmet VJ. Congenital diseases of intrahepatic bile ducts: variations on the theme "ductal plate malformation". Hepatology. 1992 Oct. 16(4):1069-83. [Medline].
Harris PC, Rossetti S. Molecular genetics of autosomal recessive polycystic kidney disease. Mol Genet Metab. 2004 Feb. 81(2):75-85. [Medline].
Losekoot M, Haarloo C, Ruivenkamp C, et al. Analysis of missense variants in the PKHD1-gene in patients with autosomal recessive polycystic kidney disease (ARPKD). Hum Genet. 2005 Nov. 118(2):185-206. [Medline].
Turkbey B, Ocak I, Daryanani K,et al. Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis (ARPKD/CHF). Pediatr Radiol. 2009 Feb. 39(2):100-11. [Medline].
Hartung EA, Guay-Woodford LM. Autosomal recessive polycystic kidney disease: a hepatorenal fibrocystic disorder with pleiotropic effects. Pediatrics. 2014 Sep. 134 (3):e833-45. [Medline].
El-Youssef M, Mu Y, Huang L, et al. Increased expression of transforming growth factor-beta1 and thrombospondin-1 in congenital hepatic fibrosis: possible role of the hepatic stellate cell. J Pediatr Gastroenterol Nutr. 1999 Apr. 28(4):386-92. [Medline].
Ozaki S, Sato Y, Yasoshima M, et al. Diffuse expression of heparan sulfate proteoglycan and connective tissue growth factor in fibrous septa with many mast cells relate to unresolving hepatic fibrosis of congenital hepatic fibrosis. Liver Int. 2005 Aug. 25(4):817-28. [Medline].
Abdullah AM, Nazer H, Atiyeh M, Ali MA. Congenital hepatic fibrosis in Saudi Arabia. J Trop Pediatr. 1991 Oct. 37(5):240-3. [Medline].
Ovchinsky N, Moreira RK, Lefkowitch JH, Lavine JE. Liver biopsy in modern clinical practice: a pediatric point-of-view. Adv Anat Pathol. 2012 Jul. 19 (4):250-62. [Medline].
Al-Lawati TT. Fibropolycystic disease of the liver and kidney in Oman. Arab J Gastroenterol. 2013 Dec. 14 (4):173-5. [Medline].
Arikan C, Ozgenc F, Akman SA, et al. Impact of liver transplantation on renal function of patients with congenital hepatic fibrosis associated with autosomal recessive polycystic kidney disease. Pediatr Transplant. 2004 Dec. 8(6):558-60. [Medline].
Dagli U, Atalay F, Sasmaz N, et al. Caroli's disease: 1977-1995 experiences. Eur J Gastroenterol Hepatol. 1998 Feb. 10(2):109-12. [Medline].
Al-Bhalal L, Akhtar M. Molecular basis of autosomal recessive polycystic kidney disease (ARPKD). Adv Anat Pathol. 2008 Jan. 15(1):54-8. [Medline].
Ananthakrishnan AN, Saeian K. Caroli's disease: identification and treatment strategy. Curr Gastroenterol Rep. 2007 Apr. 9(2):151-5. [Medline].
Braga AC, Calheno A, Rocha H, Lourenco-Gomes J. Caroli's disease with congenital hepatic fibrosis and medullary sponge kidney. J Pediatr Gastroenterol Nutr. 1994 Nov. 19(4):464-7. [Medline].
Brancatelli G, Federle MP, Vilgrain V, et al. Fibropolycystic liver disease: CT and MR imaging findings. Radiographics. 2005 May-Jun. 25(3):659-70. [Medline].
Gocmen R, Akhan O, Talim B. Congenital absence of the portal vein associated with congenital hepatic fibrosis. Pediatr Radiol. 2007 Sep. 37(9):920-4. [Medline].
Gunay-Aygun M, Font-Montgomery E, Lukose L, Tuchman Gerstein M, Piwnica-Worms K, Choyke P. Characteristics of congenital hepatic fibrosis in a large cohort of patients with autosomal recessive polycystic kidney disease. Gastroenterology. 2013 Jan. 144(1):112-121.e2. [Medline].
Gunay-Aygun M, Tuchman M, Font-Montgomery E, et al. PKHD1 sequence variations in 78 children and adults with autosomal recessive polycystic kidney disease and congenital hepatic fibrosis. Mol Genet Metab. 2010 Feb. 99(2):160-73. [Medline].
Ling SC. Congenital cholestatic syndromes: what happens when children grow up?. Can J Gastroenterol. 2007 Nov. 21(11):743-51. [Medline].
McEvoy CF, Suchy FJ. Biliary tract disease in children. Pediatr Clin North Am. 1996 Feb. 43(1):75-98. [Medline].
Miller WJ, Sechtin AG, Campbell WL, Pieters PC. Imaging findings in Caroli's disease. AJR Am J Roentgenol. 1995 Aug. 165(2):333-7. [Medline].
Nakanuma Y, Harada K, Sato Y, Ikeda H. Recent progress in the etiopathogenesis of pediatric biliary disease, particularly Caroli's disease with congenital hepatic fibrosis and biliary atresia. Histol Histopathol. 2010 Feb. 25(2):223-35. [Medline].
Nazer D, Nazer H. Congenital Hepatic Fibrosis. Elzouki, Harfi, Nazer, Stapleton, et al. Textbook of Clinical Pediatrics. 2nd. Berlin-Heidelberg: Springer-Verlag; 2012. 3: 2013-16; Chapter 208.
Poala SB, Bisogno G, Colombatti R. Thrombocytopenia and splenomegaly: an unusual presentation of congenital hepatic fibrosis. Orphanet J Rare Dis. 2010. 5:4. [Medline].
Srinath A, Shneider BL. Congenital hepatic fibrosis and autosomal recessive polycystic kidney disease. J Pediatr Gastroenterol Nutr. 2012 May. 54(5):580-7. [Medline].
Suchy FJ. Liver disease in children. Mosby Yearbook. St Louis, MO: Mosby Year Book Inc; 1994.
Yonem O, Ozkayar N, Balkanci F, et al. Is congenital hepatic fibrosis a pure liver disease?. Am J Gastroenterol. 2006 Jun. 101(6):1253-9. [Medline].